References
1. Van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody
panels for standardized n-dimensional flow cytometric immunophenotyping
of normal, reactive and malignant leukocytes. Leukemia .
2012;26(9):1908-1975. doi:10.1038/leu.2012.120
2. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to
intensive therapy in multiple myeloma: results of the prospective
IFM2013-04 trial. 2016. doi:10.1182/blood-2016-01
3. Tchernonog E, Faurie P, Coppo P, et al. Clinical characteristics and
prognostic factors of plasmablastic lymphoma patients: Analysis of 135
patients from the LYSA group. Ann Oncol . 2017;28(4):843-848.
doi:10.1093/annonc/mdw684
4. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic
lymphomas of the oral cavity: A new entity associated with the human
immunodeficiency virus infection. Blood . 1997;89(4):1413-1420.
doi:10.1182/blood.v89.4.1413
5. Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative
plasmablastic lymphoma: Not in the mouth. Clin Lymphoma, Myeloma
Leuk . 2011;11(2):185-189. doi:10.1016/j.clml.2011.03.008
6. Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative
large-cell lymphoma with plasmablastic features: A clinically
heterogenous spectrum in both HIV-positive and -negative patients.Ann Oncol . 2004;15(11):1673-1679. doi:10.1093/annonc/mdh399
7. Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL.
Plasmablastic Lymphoma in HIV-Positive Patients. Am J Surg
Pathol . 2005;29(12):1633-1641. doi:10.1097/01.pas.0000173023.02724.1f
8. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES,
Taddesse-Heath L. Plasmablastic lymphoma with MYC translocation:
evidence for a common pathway in the generation of plasmablastic
features HHS Public Access. Mod Pathol . 2010;23(7):991-999.
doi:10.1038/modpathol.2010.72
9. Meer S, Perner Y, McAlpine ED, Willem P. Extraoral plasmablastic
lymphomas in a high human immunodeficiency virus endemic area.Histopathology . 2020;76(2):212-221. doi:10.1111/his.13964
10. Vega F, Chang C-C, Medeiros LJ, et al. Plasmablastic lymphomas and
plasmablastic plasma cell myelomas have nearly identical
immunophenotypic profiles. Mod Pathol . 2005;18:806-815.
doi:10.1038/modpathol.3800355
11. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of
plasmablastic lymphoma. Blood . 2015;125(15):2323-2330.
doi:10.1182/blood-2014-10-567479
12. Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison
of plasmablastic lymphoma in HIV-positive, immunocompetent, and
posttransplant patients: single-center series of 25 cases and
meta-analysis of 277 reported cases. Am J Surg Pathol .
2014;38(7):875-886. doi:10.1097/PAS.0000000000000234
13. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, et al.
Aggressive large B-cell lymphoma with plasma cell differentiation:
Immunohistochemical characterization of plasmablastic lymphoma and
diffuse large B-cell lymphoma with partial plasmablastic phenotype.Haematologica . 2010;95(8):1342-1349.
doi:10.3324/haematol.2009.016113
14. Tominaga N, Katagiri S, Hamaguchi Y, et al. Plasma cell leukaemia of
non-producer type with missing light chain gene rearrangement. Br
J Haematol . 1988;69(2):213-218. doi:10.1111/j.1365-2141.1988.tb07624.x
15. Kyle RA, Child JA, Anderson K, et al. Criteria for the
classification of monoclonal gammopathies, multiple myeloma and related
disorders: A report of the International Myeloma Working Group. Br
J Haematol . 2003;121(5):749-757. doi:10.1046/j.1365-2141.2003.04355.x
16. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR.
Serum free light-chain measurements for identifying and monitoring
patients with nonsecretory multiple myeloma. Blood .
2001;97(9):2900-2902. doi:10.1182/blood.V97.9.2900
17. Dupuis MM, Tuchman SA. OncoTargets and Therapy Dovepress
Non-secretory multiple myeloma: from biology to clinical management.
2016. doi:10.2147/OTT.S122241
18. Gran C, Uttervall K, Borg Bruchfeld J, et al. Translocation (11;14)
in newly diagnosed multiple myeloma, time to reclassify this standard
risk chromosomal aberration? Eur J Haematol . 2019;103(6):588-596.
doi:10.1111/ejh.13325
19. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed
symptomatic multiple myeloma: Updated mayo stratification of myeloma and
risk-adapted therapy (msmart) consensus guidelines 2013. Mayo Clin
Proc . 2013;88(4):360-376. doi:10.1016/j.mayocp.2013.01.019
20. Greipp PR, Miguel JS, Dune BGM, et al. International staging system
for multiple myeloma. J Clin Oncol . 2005;23(15):3412-3420.
doi:10.1200/JCO.2005.04.242
21. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology - An
independent prognostic factor with clinical and laboratory correlates:
Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by
the ECOG myeloma laboratory group. Blood . 1998;91(7):2501-2507.
doi:10.1182/blood.v91.7.2501.2501_2501_2507
22. Andres Suarez-Londono J, Rohatgi A, Antoine-Pepeljugoski C,
Braunstein MJ. Aggressive presentation of plasmablastic myeloma. 2020.
doi:10.1136/bcr-2020-234436
Table 1. Laboratory findings of the peripheral blood
examination at diagnosis and from the control blood test performed three
months earlier. (N.A.: not available)
Figure 1. A: peripheral blood smear with an erythroblast (blue
arrow) and a blastic cell (red arrow) (Wright-Giemsa, ×1000), B and C:
bone marrow smear with pleomorphic blastic cells with immature chromatin
and a conspicuous nucleolus. Some blast cells display a distinctive
perinuclear Golgi zone (C) (Wright-Giemsa, ×1000).
Figure 2. A. Bone marrow trephine biopsy with dense diffuse
infiltrate consisting of atypical plasma cells (H&E, ×400), B. IHC of
CD138+ plasma cells (x400).